Abstract
This chapter describes how medicines have been discovered in the past and comprehensively reviews how drug discovery and development are being conducted nowadays. Today, a detailed molecular understanding of the disease is of paramount importance for the successful development of new medicines. The discovery and development process can be divided into several main steps, namely target identification and validation, lead identification and optimization , pre-clinical and clinical development. The validated therapeutic target takes centre stage in this process, as it determines the mode of action of a therapy. The chapter further discusses experimental approaches to target validation and important concept related to therapeutic targets such as oncogene addiction and synthetic lethality. Once a validated therapeutic target is available the actual drug discovery process that might include serendipity, chemical modification of bioactive molecules, rational drug discovery or random screening can begin. Further development of the identified drug candidates involves the optimization of its physical and chemical properties including its absorption, distribution, metabolism and excretion (ADME) and toxicity. During preclinical development scientists evaluate if the drug candidate is safe and works, can be delivered and manufactured, and therefore can be further tested in humans. The clinical evaluation in patients is divided into three different phases with different objectives and participants. The chapter describes the design of clinical trials and the approval process for a new drug.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Benson JD et al (2006a) Validating cancer drug targets. Nature 441:451–456. https://doi.org/10.1038/nature04873
Brehm MA, Shultz LD, Greiner DL (2010) Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 17:120–125. https://doi.org/10.1097/MED.0b013e328337282f
Cancer Genome Atlas Research N et al (2013) The cancer genome atlas pan-cancer analysis project. Nat Genet 45:1113–1120. https://doi.org/10.1038/ng.2764
Drews J (2000) Drug discovery: a historical perspective. Science 287:1960–1964
Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bosse R, Bielefeld M (2008) The use of AlphaScreen technology in HTS: current status. Curr Chem Genom 1:2–10. https://doi.org/10.2174/1875397300801010002
Faller B (2008) Artificial membrane assays to assess permeability. Curr Drug Metab 9:886–892
Ferreira BI, Hill R, Link W (2015) Special review: caught in the crosshairs: targeted drugs and personalized medicine. Cancer J 21:441–447. https://doi.org/10.1097/PPO.0000000000000161
Fleming TR, Powers JH (2012) Biomarkers and surrogate endpoints in clinical trials. Stat Med 31:2973–2984. https://doi.org/10.1002/sim.5403
Fontanarosa PB, Rennie D, DeAngelis CD (2004) Postmarketing surveillance–lack of vigilance, lack of trust. JAMA 292:2647–2650. https://doi.org/10.1001/jama.292.21.2647
Garraway LA, Sellers WR (2006) Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6:593–602. https://doi.org/10.1038/nrc1947
Gillet JP, Varma S, Gottesman MM (2013) The clinical relevance of cancer cell lines. J Natl Cancer Inst 105:452–458. https://doi.org/10.1093/jnci/djt007
Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211–219. https://doi.org/10.1038/nrd2220
Hargrave-Thomas E, Yu B, Reynisson J (2012) Serendipity in anticancer drug discovery World. J Clin Oncol 3:1–6. https://doi.org/10.5306/wjco.v3.i1.1
Hewitt RE (2011) Biobanking: the foundation of personalized medicine. Curr Opin Oncol 23:112–119. https://doi.org/10.1097/cco.0b013e32834161b8
Hidalgo M et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4:998–1013. https://doi.org/10.1158/2159-8290.CD-14-0001
Hodgson J (2001) ADMET–turning chemicals into drugs. Nat Biotechnol 19:722–726. https://doi.org/10.1038/90761
Hughes JP, Rees S, Kalindjian SB, Philpott KL (2011a) Principles of early drug discovery. Br J Pharmacol 162:1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x
Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5:689–698. https://doi.org/10.1038/nrc1691
Kim JH, Scialli AR (2011) Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122:1–6. https://doi.org/10.1093/toxsci/kfr088
Knowles J, Gromo G (2003) A guide to drug discovery: target selection in drug discovery. Nat Rev Drug Discov 2:63–69. https://doi.org/10.1038/nrd986
Kostiainen R, Kotiaho T, Kuuranne T, Auriola S (2003) Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom 38:357–372. https://doi.org/10.1002/jms.481
Lanthier M, Behrman R, Nardinelli C (2008) Economic issues with follow-on protein products. Nat Rev Drug Discov 7:733–737. https://doi.org/10.1038/nrd2636
Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474–485. https://doi.org/10.1056/NEJMra021844
Li AP (2004) Accurate prediction of human drug toxicity: a major challenge in drug development. Chem Biol Interact 150:3–7. https://doi.org/10.1016/j.cbi.2004.09.008
Liberti L, Breckenridge A, Eichler HG, Peterson R, McAuslane N, Walker S (2010) Expediting patients’ access to medicines by improving the predictability of drug development and the regulatory approval process. Clin Pharmacol Ther 87:27–31. https://doi.org/10.1038/clpt.2009.179
Lindsay MA (2003) Target discovery. Nat Rev Drug Discov 2:831–838. https://doi.org/10.1038/nrd1202
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26
Mavromoustakos T, Durdagi S, Koukoulitsa C, Simcic M, Papadopoulos MG, Hodoscek M, Grdadolnik SG (2011) Strategies in the rational drug design. Curr Med Chem 18:2517–2530
Nebert DW, Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155–1162. https://doi.org/10.1016/s0140-6736(02)11203-7
Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302. https://doi.org/10.2165/00002018-200022040-00002
Perkins R, Fang H, Tong W, Welsh WJ (2003) Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 22:1666–1679
Pushpakom S et al (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. https://doi.org/10.1038/nrd.2018.168
Richmond A, Su Y (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1:78–82. https://doi.org/10.1242/dmm.000976
Rubin EH, Gilliland DG (2012) Drug development and clinical trials–the path to an approved cancer drug. Nat Rev Clin Oncol 9:215–222. https://doi.org/10.1038/nrclinonc.2012.22
Sams-Dodd F (2005) Target-based drug discovery: is something wrong? Drug Discov Today 10:139–147. https://doi.org/10.1016/S1359-6446(04)03316-1
Santos R et al (2017) A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16:19–34. https://doi.org/10.1038/nrd.2016.230
Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67–95. https://doi.org/10.1146/annurev.pharmtox.40.1.67
Smith C (2003) Drug target validation: hitting the target. Nature 422:341, 343, 345 passim. https://doi.org/10.1038/422341a
Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929–939. https://doi.org/10.1038/nrd3287
Sneader W (2000) The discovery of aspirin: a reappraisal. Bmj 321:1591–1594
Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G (2007) Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 6:891–903. https://doi.org/10.1038/nrd2410
Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–660. https://doi.org/10.1124/dmd.32.6.647
Waring MJ et al (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14:475–486. https://doi.org/10.1038/nrd4609
Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077–3080; discussion 3080. https://doi.org/10.1158/0008-5472.can-07-3293
Zanella F, Lorens JB, Link W (2010) High content screening: seeing is believing. Trends Biotechnol 28:237–245. https://doi.org/10.1016/j.tibtech.2010.02.005
Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73. https://doi.org/10.1177/108705719900400206
Further Reading
Benson JD, Chen YNP, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C (2006) Validating cancer drug targets. Nature 441:451–456
Eric H, Rubin EH, Gilliland DG (2012) Drug development and clinical trials—the path to an approved cancer drug. Nat Rev Clin Oncol 9:215–222
Gibbs JB (2000) Mechanism-based target identification and drug discovery in cancer research. Science 287:1969–1973
Hughes JP, Rees S, Kalindjian SB, Philpott KL (2011) Principles of early drug discovery. Br J Pharmacol 162:1239–1249
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev 3:711–715
Rho JP, Louie SG (2003) Handbook of pharmaceutical biotechnology. Pharmaceutical Products Press, New York
Sawyers C (2004) Targeted cancer therapy. Nature 432:294–297
van’t Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452:564–570
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Link, W. (2019). Drug Discovery and Development. In: Principles of Cancer Treatment and Anticancer Drug Development. Springer, Cham. https://doi.org/10.1007/978-3-030-18722-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-18722-4_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-18721-7
Online ISBN: 978-3-030-18722-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)